Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phentermine - Citius Pharmaceuticals

Next Previous
Search
Drug Profile

Phentermine - Citius Pharmaceuticals

Alternative Names: Phentermine hydrochloride; Suprenza

Latest Information Update: 30 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alpex Pharma
  • Developer Citius Pharmaceuticals Inc
  • Class Amphetamines; Anorectics; Small molecules
  • Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Market Withdrawal Obesity

Most Recent Events

  • 01 Jul 2016 Withdrawn for Obesity (Adjunctive treatment) in USA (PO)
  • 18 Sep 2014 Citius Pharmaceuticals plans additional phase II trial for Obesity in USA (PO) (Citius Pharmaceuticals, Form 8-K filed in September 2014)
  • 01 Apr 2012 Launched for Obesity (Adjunctive treatment, With exercise, behavioural modification and caloric restriction) in USA (PO, 15mg, 30mg)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top